Table 1.

Adverse event rates in the POPLAR and OAK trials in intention-to-treat populations.

Trial name	Arms	Any grade adverse events (%)	Grade 3–4 adverse events (%)	Adverse events leading to dose modification, delay or interruption (%)	Immune-related adverse events (%)
Hervst et al.13	Atezo	94.9	39	–	–
POPLAR	Atezo	96	40	24	3.2*
	Doc	96	53	33	–
OAK	Atezo	94	37	25	10.5**
	Doc	96	54	36	–

^*Pneumonitis: 6; colitis: 2; hepatitis: 2.

^**Pneumonitis: 4; increased aspartate aminotransferase: 6; increased alanine aminotransferase: 6; colitis: 4; hepatitis: 1.

Atezo, atezolizumab; Doc, docetaxel.